Equitable Trust Co. acquired a new stake in Kenvue Inc. (NYSE:KVUE – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 31,406 shares of the company’s stock, valued at approximately $631,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kistler Tiffany Companies LLC purchased a new position in Kenvue in the 2nd quarter valued at about $26,000. Tamarack Advisers LP bought a new position in shares of Kenvue during the second quarter worth about $26,000. EverSource Wealth Advisors LLC bought a new position in shares of Kenvue during the third quarter worth about $28,000. AdvisorNet Financial Inc bought a new position in shares of Kenvue during the third quarter worth about $28,000. Finally, Global Retirement Partners LLC bought a new position in shares of Kenvue during the third quarter worth about $28,000. 11.33% of the stock is owned by hedge funds and other institutional investors.
Kenvue Stock Performance
Shares of NYSE:KVUE opened at $20.87 on Wednesday. The firm’s 50 day moving average is $20.94 and its two-hundred day moving average is $21.27. Kenvue Inc. has a 52 week low of $17.82 and a 52 week high of $27.80. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.78 and a current ratio of 1.14.
Kenvue Dividend Announcement
Analysts Set New Price Targets
Several equities analysts have recently commented on KVUE shares. JPMorgan Chase & Co. reduced their price target on shares of Kenvue from $29.00 to $26.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 4th. UBS Group raised their target price on shares of Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, December 19th. The Goldman Sachs Group cut their target price on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a report on Tuesday, October 10th. Finally, Piper Sandler assumed coverage on shares of Kenvue in a report on Friday, November 17th. They issued a “neutral” rating and a $20.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Kenvue has an average rating of “Moderate Buy” and an average target price of $26.50.
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.
- Five stocks we like better than Kenvue
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Med-tech stock Conmed dips ahead of big Q4 report…opportunity?
- How to Invest in Mining Stocks
- Here’s how Abercrombie’s “Chase” strategy keeps printing money
- What is MarketRank™? How to Use it
- 4 med tech stocks with improving prognosis for 2024
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.